Q-Line Biotech
CLOSEDIPO Date: 21 May - 25 May 2026
Listing Date: 29 May 2026
Price Range
Rs.326 - Rs.343
Issue Size
214 Cr
Min Investment
₹1,30,400
Lot Size
400 Shares
Schedule of Q-Line Biotech
Issue open date
21 May 2026
Issue close date
25 May 2026
UPI mandate deadline
25 May 2026 (5 PM)
Allotment finalization
26 May 2026
Share credit
27 May 2026
Listing date
29 May 2026
Mandate end date
9 Jun 2026
Issue size
| Funds Raised in the IPO | Amount |
|---|---|
| Overall | 214 Cr |
| Fresh Issue | 214.48 Cr |
| Offer for Sale | 0 Cr |
Allotment DetailsNew
| Allotment Timeline | Details |
|---|---|
| Allotment Date | 26 May 2026 |
| Allotment Link | {Link} |
Grey Market PremiumNew
Grey Market Premium (GMP) is the premium at which the shares are traded in the grey market. It gives a fair idea about the listing price of the IPO shares. The GMP can be positive or negative based on the demand and supply of the shares in the grey market.
| Date | Ipo Price | GMP | Estimated Listing Price |
|---|---|---|---|
| 24 May 2026 | ₹343 | ₹125 | ₹468 (36.44%) |
| 23 May 2026 | ₹343 | ₹127 | ₹470 (37.03%) |
| 22 May 2026 | ₹343 | ₹127 | ₹470 (37.03%) |
| 20 May 2026 | ₹343 | ₹141 | ₹484 (41.11%) |
| 19 May 2026 | ₹343 | ₹110 | ₹453 (32.07%) |
| 18 May 2026 | ₹343 | ₹69 | ₹412 (20.12%) |
| 17 May 2026 | ₹343 | ₹0 | ₹343 (0%) |
Performance Q-Line Biotech
| Issue Price | Listing Gain | Current Market Price | P/L |
|---|---|---|---|
| Rs.326 - Rs.343 | .... | .... | .... |
About Q-Line Biotech
Q-Line Biotech Limited is engaged in the development, manufacturing, and marketing of diagnostic reagents, consumables, and in-vitro diagnostic (IVD) equipment for healthcare and diagnostic applications. The company supplies products such as clinical chemistry reagents, haematology and immunodiagnostic products, molecular diagnostic kits, rapid test kits, point-of-care devices, analysers, laboratory consumables, and diagnostic instruments to diagnostic laboratories, hospitals, and medical colleges. It also provides annual maintenance and after-sales services for medical equipment. During the Covid-19 pandemic, the company developed products including RT-PCR kits, RNA extraction kits, and VTM kits. Q-Line Biotech operates multiple manufacturing facilities, warehouses, and offices in Lucknow, Uttar Pradesh, Delhi, Kolkata and Bhubaneswar. Its manufacturing operations include indigenous production of reagents and diagnostic analysers, while some products are manufactured under technical collaborations with international companies.
| Founded in | 2010 |
| Managing director | Mr Saurabh Garg |
| Parent organization |
Financial Overview
Strengths
- Q-Line Biotech has established manufacturing capabilities with a focus on R&D and quality control.
- The company offers a diversified product portfolio across multiple IVD segments.
- It has a widespread distribution network across all four regions of India.
- The company has long-standing relationships with customers in the diagnostics industry.
- Q-Line Biotech has shown a track record of healthy financial performance.
Risks
- Any disruption at its manufacturing or R&D facilities could affect operations and revenue.
- The company depends on third-party suppliers for key raw materials and equipment.
- A large share of revenue comes from a few major customers.
- Failure to maintain product quality could lead to recalls, penalties, or reputational damage.
- Delays in regulatory approvals or registrations may impact business operations.
Subscription Figures
| Category | Subscription (No. of times) |
|---|---|
| Qualified Institutional Buyers (QIBs) | 109.34 |
| Non-Institutional Investors (NIIs) | 105.25 |
| Retail Individual Investors (RIIs) | 66.41 |
| Employee | N/A |
| Total | 88.28 |